I-Mab (IMAB) Competitors $2.10 +0.02 (+0.96%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMAB vs. MAZE, MRVI, IOVA, URGN, TLRY, TNGX, STOK, PRME, DNTH, and PHATShould you be buying I-Mab stock or one of its competitors? The main competitors of I-Mab include Maze Therapeutics (MAZE), Maravai LifeSciences (MRVI), Iovance Biotherapeutics (IOVA), Urogen Pharma (URGN), Tilray Brands (TLRY), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Prime Medicine (PRME), Dianthus Therapeutics (DNTH), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. I-Mab vs. Its Competitors Maze Therapeutics Maravai LifeSciences Iovance Biotherapeutics Urogen Pharma Tilray Brands Tango Therapeutics Stoke Therapeutics Prime Medicine Dianthus Therapeutics Phathom Pharmaceuticals I-Mab (NASDAQ:IMAB) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership. Do analysts rate IMAB or MAZE? I-Mab presently has a consensus target price of $6.00, suggesting a potential upside of 185.71%. Maze Therapeutics has a consensus target price of $25.60, suggesting a potential upside of 48.06%. Given I-Mab's stronger consensus rating and higher probable upside, research analysts clearly believe I-Mab is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score I-Mab 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Do institutionals & insiders hold more shares of IMAB or MAZE? 38.4% of I-Mab shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher valuation & earnings, IMAB or MAZE? Maze Therapeutics has higher revenue and earnings than I-Mab. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioI-MabN/AN/A-$22.23MN/AN/AMaze Therapeutics$167.50M4.52$52.23MN/AN/A Is IMAB or MAZE more profitable? Maze Therapeutics' return on equity of 0.00% beat I-Mab's return on equity.Company Net Margins Return on Equity Return on Assets I-MabN/A -19.81% -18.63% Maze Therapeutics N/A N/A N/A Does the media prefer IMAB or MAZE? In the previous week, Maze Therapeutics had 4 more articles in the media than I-Mab. MarketBeat recorded 7 mentions for Maze Therapeutics and 3 mentions for I-Mab. Maze Therapeutics' average media sentiment score of 0.35 beat I-Mab's score of 0.15 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Maze Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMaze Therapeutics beats I-Mab on 8 of the 12 factors compared between the two stocks. Get I-Mab News Delivered to You Automatically Sign up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMAB vs. The Competition Export to ExcelMetricI-MabMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$171.49M$3.04B$5.66B$9.45BDividend YieldN/A2.49%4.01%4.02%P/E RatioN/A21.3528.5520.10Price / SalesN/A275.25417.2988.13Price / CashN/A41.6635.9658.29Price / Book0.858.158.545.79Net Income-$22.23M-$55.10M$3.24B$258.18M7 Day Performance-2.33%7.51%4.75%3.80%1 Month Performance-14.63%21.60%12.89%14.59%1 Year Performance46.85%6.49%36.03%18.91% I-Mab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMABI-Mab2.8812 of 5 stars$2.10+1.0%$6.00+185.7%+46.5%$171.49MN/A0.00380Analyst DowngradeGap DownMAZEMaze TherapeuticsN/A$15.74+4.6%$23.50+49.3%N/A$689.41M$167.50M0.00121News CoverageAnalyst ForecastGap UpMRVIMaravai LifeSciences3.5994 of 5 stars$2.67-2.2%$6.64+148.6%-69.7%$679.94M$259.18M-2.34610IOVAIovance Biotherapeutics4.6368 of 5 stars$2.01+7.5%$12.22+508.1%-62.4%$671.20M$164.07M-1.62500Analyst ForecastOptions VolumeGap UpHigh Trading VolumeURGNUrogen Pharma4.4453 of 5 stars$14.49+1.8%$32.86+126.8%+4.7%$668.13M$90.40M-4.56200TLRYTilray Brands1.7511 of 5 stars$0.66+13.1%$1.92+191.8%-59.1%$661.07M$788.94M-0.632,650Upcoming EarningsOptions VolumeGap UpTNGXTango Therapeutics1.3453 of 5 stars$6.09+2.7%$12.20+100.3%-32.5%$660.12M$40.99M-4.9990Gap UpSTOKStoke Therapeutics4.2577 of 5 stars$12.06+1.7%$24.75+105.2%-10.4%$658.48M$36.56M15.27100Gap UpPRMEPrime Medicine3.8618 of 5 stars$4.80+10.3%$10.08+110.1%-16.4%$645.57M$3.85M-2.34234High Trading VolumeDNTHDianthus Therapeutics1.0627 of 5 stars$20.03-0.1%$53.00+164.6%-25.8%$644.17M$6.24M-6.9580PHATPhathom Pharmaceuticals4.3891 of 5 stars$9.06-1.3%$17.50+93.2%-33.5%$632.48M$55.25M-1.73110 Related Companies and Tools Related Companies Maze Therapeutics Alternatives Maravai LifeSciences Alternatives Iovance Biotherapeutics Alternatives Urogen Pharma Alternatives Tilray Brands Alternatives Tango Therapeutics Alternatives Stoke Therapeutics Alternatives Prime Medicine Alternatives Dianthus Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMAB) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
